MTOR and neoplasm: We propose that OCTA may serve as a more sensitive modality to assess the efficacy of mTOR inhibitors for TSC-associated RAHs, considering that blood flow is essential for tumor growth and that changes in RPC or SCP vascular density may precede the changes in maximal thickness of RAHs.